

1 . - . "

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
control number.

Output

Out control number

Substitute for form 1449A/PTO Compl te if Known **Application Number** 10/060.941 INFORMATION DISCLOSURE Filing Date January 29, 2002 STATEMENT BY APPLICANT First Named Inventor Julie Dyall Art Unit (use as many sheets as necessary) **Examiner Name** Sheet Attorney Docket Number 3219/5 of

			U.S. PAT	ENT DOCUMENTS	
Examiner Initials		Document Number Number - Kind Code <sup>2</sup> (if known	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		us-`			Vigeree rippedi
		us- :			
	*****************	US-			
		US- \ C			
		us-			
			<b>X</b>		
		US-			
		US-			
		US-			
		US-	1 1		
		US-			
		US-	<i>'</i>		
		US-	\		
		US-			
*		us-		व्	
		US-		2	
		US-		7	
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code3 -Number4 - Kind Code4 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6
***************************************		MATERIAL DESCRIPTION OF THE PROPERTY OF THE PR				
						ļ

Examiner Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if

Under the Paperwork Reduction Act of the no persons and control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B/PTO

## **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of

C	mpl t if Known
Application Number	10/060,941
Filing Date	January 29, 2002
First Named Inventor	Julie Dyall
Group Art Unit	1648
Examiner Name	won tman
Attorney Docket Number	3219/5

<u></u>	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Exam Initia		Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T <sup>2</sup>		
D.		1	AGAPOV, E. V. et al., Noncytopathic Sindbis virus RNA vectors for heterologous gene expression. Proc. Natl. Acad. Sci. USA. 95:12989-12994 (1998).			
		2.	BLIGHT, K. J. et al., Efficient initiation of HCV RNA replication in cell culture. Science. 290:1972-4 (2000).			
		3.	BREDENBEEK, P. J. et al., Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J. Virol. 67(11):6439-46 (1993).	***************************************		
		4	BURGART, L. J. et al., Multiplex polymerase chain reaction. Mod. Pathol. 5(3):320-3 (1992).			
		5 _	COLLINS, P. L. et al. Transcription elongation factor of respiratory syncytial virus, a nonségmented negative-strand RNA virus. Proc. Natl. Acad. Sci. USA. 93:81-85 (1996).			
		6.	ELNIFRO, E. M. et al., Multiplex PCR: optimization and application in diagnostic virology. Clin. Microbiol. Rev. 13(4):559-70 (2000).			
-	,	7.	FROLOV, I. et al., 1999. Selection of RNA replicons capable of persistent noncytopathic replication in mammalian cells. J. Virol. 73(5):3854-65 (1999).			
		8.	FROLOV, I. et al., Alphavirus-based expression vectors: strategies and applications. Proc. Natl. Acad. Sci. USA. 93:11371-7 (1996).	777410411141		
		9	GRENTZMANN, G. et al., A dual-luciferase reporter system for studying recoding signals. RNA. 4:479-86 (1998).			
		10	FAN, J. et al., Rapid simultaneous diagnosis of infections with Respiratory Syncytial Viruses A and B, Influenza Viruses A and B, and Human Parainfluenza Virus types 1, 2, and 3 by multiplex quantitative reverse transcription- polymerase chain reaction-enzyme hybridization assay (Hexaplex). Clin. Infect. Dis 26:1397-402 (1998).			
		11	GRONDAHL, B. et al., Rapid identification of nine microorganisms causing acute respiratory tract infections by single-tube multiplex reverse transcription-PCR: feasibility study. J. Clin. Microbiol. 37(1):1-7 (1999).			
_						

Examiner Date Signature Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
control number. control number.

Complete if Known Substitute for form 1449B/PTO 10/060,941 **Application Number** INFORMATION DISCLOSURE January 29, 2002 Filing Date STATEMENT BY APPLICANT First Named Inventor Julie Dyall Group Art Unit (use as many sheets as necessary) Examiner Name Sheet 3 of Attorney Docket Number 3219/5

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т
	12	RICE, C. M., et al. 1987. Production of infectious RNA transcripts from Sindbis virus cDNA clones: mapping of lethal mutations, rescue of a temperature-sensitive marker, and in vitro mutagenesis to generate defined mutants J Virol. 61:3809-19.	
	13	RICE, C. M., et al. 1989. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation New Biol. 1:285-96.	
	14	JUNGKIND, D., 1996. Evaluation of automated COBAS AMPLICOR PCR system for detection of several infectious agents and its impact on laboratory management J Clin Microbiol. 34:2778-83.	
	15	GRONDAHL, et al. 1999. Rapid identification of nine microorganisms causing acute respiratory tract infections by single-tube multiplex reverse transcription-PCR: feasibility study J Clin Microbiol. 37:1-7.	
	16 <sup>.</sup>	PARSONS, S. J., 2000. Use of a dual firefly and Renilla luciferase reporter gene assay to simultaneously determine drug selectivity at human corticotrophin releasing hormone 1 and 2 receptors Anal Biochem. 281:187-92.	
	17	PLUMPTON M., et al. 1995 A high capacity assay for inhibitors of human papillomavirus DNA replication. Biotechnology (NY) Nov; 13(11):1210-4	
Prince ANALAS			
		· .	
			***************************************
		,	
	7		_

Considered \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.